Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sander Kelderman

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Science (New York, N.Y.)|May 21, 2016
Targeting of cancer neoantigens with donor-derived T cell receptor repertoiresErlend Strønen, Mireille Toebes, Sander Kelderman, et al.
European Journal of Immunology|March 24, 2016
Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapySander Kelderman, Bianca Heemskerk, Lorenzo Fanchi, et al.
Science Translational Medicine|September 19, 2014
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell responsePia Kvistborg, Daisy Philips, Sander Kelderman, et al.
Acta Oncologica (Stockholm, Sweden)|April 24, 2013
Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)Sander Kelderman, Monique K van der Kooij, Alfons J M van den Eertwegh, et al.
Nature Medicine|December 5, 2018
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancersWouter Scheper, Sander Kelderman, Lorenzo F Fanchi, et al.
Cell|August 14, 2018
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor OrganoidsKrijn K Dijkstra, Chiara M Cattaneo, Fleur Weeber, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2014
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanomaSander Kelderman, Bianca Heemskerk, Harm van Tinteren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2015
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic CellsGerty Schreibelt, Kalijn F Bol, Harm Westdorp, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Science (New York, N.Y.)|May 21, 2016
Targeting of cancer neoantigens with donor-derived T cell receptor repertoiresErlend Strønen, Mireille Toebes, Sander Kelderman, et al.
European Journal of Immunology|March 24, 2016
Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapySander Kelderman, Bianca Heemskerk, Lorenzo Fanchi, et al.
Science Translational Medicine|September 19, 2014
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell responsePia Kvistborg, Daisy Philips, Sander Kelderman, et al.
Acta Oncologica (Stockholm, Sweden)|April 24, 2013
Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)Sander Kelderman, Monique K van der Kooij, Alfons J M van den Eertwegh, et al.
Nature Medicine|December 5, 2018
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancersWouter Scheper, Sander Kelderman, Lorenzo F Fanchi, et al.
Cell|August 14, 2018
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor OrganoidsKrijn K Dijkstra, Chiara M Cattaneo, Fleur Weeber, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2014
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanomaSander Kelderman, Bianca Heemskerk, Harm van Tinteren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2015
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic CellsGerty Schreibelt, Kalijn F Bol, Harm Westdorp, et al.
Pageof 2